Académique Documents
Professionnel Documents
Culture Documents
6-2015
This Thesis is brought to you for free and open access by OHSU Digital Commons. It has been accepted for inclusion in Scholar Archive by an
authorized administrator of OHSU Digital Commons. For more information, please contact champieu@ohsu.edu.
By
Jeremy Dorance ONeal
June 2015
Certificate of Approval
TABLE OF CONTENTS
Acknowledgments .................................................................................................................. iii
Abstract ...................................................................................................................................... iv
Introduction ............................................................................................................................... 6
Background ................................................................................................................................ 9
Methods ..................................................................................................................................... 21
Study Design ...................................................................................................................................... 21
Patient Population .......................................................................................................................... 21
Inclusion and Exclusion Criteria ................................................................................................ 22
Table 1: Inclusion/Exclusion Criteria ................................................................................................. 22
Variables Requested and Method/Equipment Utilized ..................................................... 22
Table 2: Variables and Corresponding Recording Methods/Equipment ............................. 24
Statistical Analysis .......................................................................................................................... 25
Results ........................................................................................................................................ 27
Specific Aim 1: Description of OHSUs HIV/AIDS Clinics Vitamin D Supplementation
Regimens ............................................................................................................................................ 27
Diagram 1: Data Cleaning Sample Counts ......................................................................................... 28
Table 3: Patient Characteristics based on Regimen and Vitamin D Type ............................ 30
(n=228)............................................................................................................................................................ 30
Figure 1: 25-(OH)D Change by Regimen ........................................................................................... 31
Figure 2: Vitamin D Deficiency and Insufficiency Before/After Supplementation .......... 35
Specific Aim 2: Change of Serum 25-(OH)D Among Vitamin D Regimens ................... 36
Specific Aim 3: Effect of BMI on Change in Serum 25-(OH)D in HIV-Infected Patients
................................................................................................................................................................ 39
Figure 3: Change in 25-(OH)D Categorized by BMI ...................................................................... 41
Figure 4: Change in 25-(OH)D Categorized by BMI, Underweight and Normal Weight
Combined........................................................................................................................................................ 42
Discussion ................................................................................................................................. 43
Prevalence of Vitamin D Deficiency Among HIV-Infected Patients ............................... 43
ii
Acknowledgments
First and foremost, I must recognize my parents for their support throughout my
entire academic career beginning with the first hug and kiss as I anxiously entered
kindergarten, to now, as I near completion of my graduate program. They have not only
provided emotional support but gave me the opportunity to understand the best path to
pursue. Because of this I am in Portland, Oregon, and following my true passion:
dietetics and nutrition.
Beyond the support of my family, I have been blessed with calling the most
supportive and unique individuals my friends. They have supported me through stressful
moments, which I feared Id never escape, and they have a sense of humility unlike most.
Their gentle reminders kept me on this path even after I lost my vision.
Moving forward to the present, I must acknowledge the support of my thesis
advisory committee. Dr. P. Todd Korthuis, Dr. Joyanna Hansen (Joy, preferred), Dr.
Melanie Gillingham, and Devon Flynn have all been part of this thoughtful and
rewarding journey. Additionally, without Dr. Kathleen Holtons persistence with helping
me to develop my thesis topic and connecting with my current mentor, Dr. P. Todd
Korthuis, I would not have had the same level of passion compiling my thesis.
Additionally, both Mike Lasarev and Hongli Yang were instrumental in completing my
data cleaning, variable creation, and resultant statistical analyses.
Finally, I must share my appreciation to Jeri Finn, the Dietetic Internship Director
for forwarding my request to expand my Dietetic Internship to include Master of Science
degree. If it were not for her efforts, this thesis would not exist.
On one final note, along this academic journey Ive acknowledged my weaknesses and
iii
realized my strengths. Though my growth has been complimented by both successes and
failures, Ive learned to embrace the danger of failure instead of avoiding it completely.
Even if the result was not desirable, it has always allowed me to further discover myself.
Thank you to everyone that has made this possible for me.
iv
Abstract
Vitamin D deficiency may be common among HIV infected individuals. Similar
to individuals not affected by HIV, HIV-infected patients are affected by limited UV-B
exposure and vitamin D deficient diet. However, HIV-infected patients may be at
increased risk for insufficient vitamin D due to antiretroviral medication regimens that
affect vitamin D metabolism and fat malabsorption due to HIV-related inflammation.
In this historical chart review, we examined the prevalence of vitamin D
insufficiency and assessed the comparative effectiveness of varying vitamin D repletion
regimens in an HIV-infected cohort. The study population comprised patients from an
outpatient HIV clinic who had vitamin D measured and who were prescribed a vitamin D
repletion regimen. Demographic and clinical data were extracted from medical records,
including 25-(OH)D concentrations drawn at baseline and follow-up appointments.
Specific factors were analyzed in association with the main outcome of change in serum
25-(OH)D, including season of blood draw and body mass index. Differences in the
change in 25-(OH)D between regimens were calculated by one-way ANOVA.
A total of 228 subjects were studied. There was a high prevalence of 25-(OH)D
insufficiency (<30 ng/mL; 71.4%, 160/224). Vitamin D supplementation reduced this
prevalence by 10.2% after an average of 14.0 6.3 months (range: 0.7 49.0 months). A
significant difference in change in 25-(OH)D concentration among vitamin D regimens
was noted between the repletion/maintenance regimen (50,000 IU D2 weekly/400-5,000
D2 or D3 IU daily) and the single vitamin D3 (chole-) based regimens (adjusted p-value =
0.047). Interestingly, when grouped by dosage strength no significant differences in
change in serum 25-(OH)D were noted (adjusted p-value = 0.489). When patients were
iv
Introduction
Specific Aims
The objective of this research project is to determine which regimen of vitamin D
supplementation is the most effective for normalizing serum 25-(OH)D levels among
HIV-infected patients. The timeframe between baseline and follow-up appointments
ranged from 10-17 months in this study population. This historical chart review will
utilize Oregon Health and Science Universitys (OHSU) HIV/AIDS clinics electronic
medical record (EMR) as part of IRB# 464: Prospective OHSU HIV Database Core
Protocol, which collects various clinical data, modified to include serum 25-(OH)D
levels among patients receiving care in the OHSU HIV/AIDS clinic.
Aim 1: To describe the OHSU HIV/AIDS clinics vitamin D supplementation regimens
Aim 2: To use historical data to compare the mean change of serum 25-(OH)D levels
between vitamin D supplementation regimens among patient in this HIV/AIDS clinic
after an average range of 10-17 months of supplementation.
Hypothesis 1: Patients prescribed a high dose of vitamin D will have a
significantly higher serum 25-(OH)D levels after an average range of 10-17
months of supplementation when compared to patients who were prescribed any
other vitamin D supplementation regimen.
Aim 3: To determine if obesity within an HIV-infected population significantly affects
serum 25OHD levels after vitamin D supplementation (all regimens).
Hypothesis 2: HIV-infected patients with a baseline BMI > 30 kg/m2 will have a
significantly lower mean change of serum 25-(OH)D than those patients with a
BMI <29 kg/m2.
Background
living in the United States.28-30 Though the estimated prevalence of vitamin D deficiency
among HIV-infected patients is similar to that of adults living in the United States, HIVinfected patients have additional risk factors for vitamin D deficiency than their non HIVinfected peers.
this study will analyze the proportion of obese HIV-infected individuals, compared to
non-obese HIV-infected individuals to determine if there is a higher proportion of VDD
in this group. Obesity has become more of a chronic health concern for HIV-infected
individuals than wasting syndrome due to the advancement of HIV-antiretroviral
regimens, making this research question highly relevant.25
The increase of obesity prevalence amongst HIV-infected patients is often
explained by patients anti-retroviral (ARV) treatment.25 Additionally, ARV treatment
interacts with vitamin D metabolism.1 In a cross-sectional study that divided HIVinfected patients into tertiles based on CD4+ T-lymphocyte counts, the highest CD4+
tertile (500 cells/mm3) and the lowest CD4+ tertile (0-199 cells/mm3) had 73.9% and
64.2% of the patients respectively who consumed deficient amounts of vitamin D (<67%
RDI).34 Even HIV antiretroviral (ARV) based regimens have the potential to lower
vitamin D activity through reduced 1,25-dihydroxyvitamin D levels, as compared to
those who are not on an ARV-regimen, regardless of the type or regimen of ARV.35 HIVprotease inhibitors and reverse transcriptase inhibitors, most commonly, have been
associated with the lowest serum 1,25-dihydroxyvitamin D levels. HIV protease
inhibitors (PIs) indinavir, ritonavir, and nelnavir and reverse transcriptase inhibitor
efavirenz interfere with the metabolic pathways of vitamin D through inhibition of
hepatic cytochrome p45027B1 and p45027B2 (CYP27B1 and CYP27B2, respectively).
CYP45027B1 and CYP45027B2 are critical for the first hydroxylation of vitamin D and
resultant serum 25(OH) D concentration.35, 36 Beyond medications, co-infections such as
Mycobacterium avium complex (MAC) are associated with a lower serum 1,25dihydroxyvitamin D compared to those without the co-infection in AIDS-diagnosed
10
patients. Furthermore, a MAC co-infection may activate the TNF system that has been
positively correlated with the degree of 1,25-dihydroxyvitamin D deficiency. MAC is
also associated with increased morbidity in AIDS diagnosed patients.33
HIV potentially causes intestinal fat malabsorption due to the virus infecting the
distal small intestinal mucosa; however, this has only been studied in Rhesus monkeys
infected with simian immunodeficiency virus (SIV), HIVs precursor. 37 Vitamin D has
been shown to reduce overall inflammation in HIV-infected patients and could possibly
reduce malabsorption if stores are adequate.15, 35
11
12
and 23.48 In addition to the molecular differences, vitamin D2 also has a decreased
affinity for vitamin D-receptors (VDRs) when compared to vitamin D3.50 Despite the side
chain difference and decreased VDR affinity, research in rats suggests there is
comparable benefit from vitamin D2 when dosage is about four times greater than vitamin
D3.51 However, when comparing toxicities in rhesus monkeys, mega-doses of vitamin D2
resulted in significantly less poly-organ mineral deposition than vitamin D3.52 In a recent
review of various vitamin D supplementation regimens, Tripkovic et al. (2012) concluded
cholecalciferol (D3) supplementation resulted in a greater increase in serum 25-(OH)D
concentrations compared to ergocalciferol supplementation (D2); however, the metabolic
evidence to support this finding is limited in the current literature.53 Since HIV can lead
to multiple malabsorptive effects, potency of the vitamin D supplement is vital. Based on
this evidence, vitamin D3, cholecalciferol, should be more potent and effective for
25OHD repletion within an HIV-infected population than vitamin D2, ergocalciferol.
13
14
examinations to note any signs of AIDS. The serum viral load has the strongest
association with progression to AIDS and death over CD4+ T-lymphocyte counts. Viral
load also predicts the rate of decrease of CD4+ T-lymphocytes. It has been suggested that
measurement of plasma HIV-1 RNA viral load and CD4+ T-lymphocytes should be
considered to fully understand the disease state.63 Typically, a viral load greater than
100,000 copies/mL is associated with a greater likelihood of developing AIDS and
mandates initiating treatment, while a viral load count less than 10,000 copies/mL is
considered low-positive and associated with a decreased risk of developing AIDS.64
CD4 percentage in an individuals lifetime or the nadir CD4 count percentage determines
the extent of overall medical care needed for that individual patient.65
It is important to note that HIV-infected patients can live without being diagnosed
with AIDS in their lifetime. In the United States, 32,052 HIV-infected patients were
diagnosed with AIDS in 2011 out of 1.1 million total HIV-infected patients at that time.68
Based on this, the risk of AIDS diagnoses in an HIV-infected patient population is about
2.9%. Even without ARV treatment, an HIV-infected individual can live up to 10 years
without ever receiving an AIDS diagnosis.69
16
17
18
19
20
Methods
Study Design
This historical chart review was conducted with data acquired from Oregon
Health and Science University (OHSU) HIV/AIDS clinic case registry located in
Portland, Oregon (latitude: 45.49). Within this data set, patient names were assigned a
unique identifier by an external third party and fully de-identified. Patient data was
collected from January 2011 to January 2014 in order to allow for a robust dataset.
Importantly, not every patient had 25-(OH)D screening or was prescribed a vitamin D
supplementation regimen in this dataset; individuals without two 25-(OH)D screenings or
not prescribed a vitamin D supplementation regimen were omitted from the statistical
analysis. This study was approved by OHSUs Institutional Review Board as part of Dr.
P. Todd Korthuis Prospective OHSU HIV Database Core Protocol (Institutional Review
Board protocol #464). Individual IRB modifications regarding specific research analyses
were submitted separately under this protocol and approved on September 5th, 2014 (ID#
CR00021877).
Patient Population
For the Prospective OHSU Database Core Protocol, clinical and administrative
data from all adult patients (>18 years of age) receiving outpatient care through OHSUs
HIV/AIDS clinic was collected. This protocol included a patient waiver of consent
informing the patients of potential research opportunities and specific de-identification
procedures. Patient medical record numbers were used to query the OHSU electronic
medical record in order to extract data entered during each clinical visit.
21
The body mass index (BMI) for the third specific aim was calculated as weight in
kilograms (kg) and divided by the square of height in meters from measurements
recorded during the same appointment as when the vitamin D supplementation regimen
was prescribed (baseline BMI). If height was not measured at the appointment when
vitamin D supplementation regimen was prescribed, the most recent height was used
instead.
OHSU Central Lab collected a venous blood sample for the measurement of
serum 25-(OH)D concentration regardless of the fed or fasted status of the patient.
Antecubital venous blood samples were ordered by the HIV/AIDS clinic 2 to 3 weeks
before the patients appointment to allow time for the samples analyses. At minimum, 3
mL of venous blood were collected in a red top tube and analyzed in a DiaSorin
LIAISON 25-OH Vitamin D Total Assay. The DiaSorin LIAISON 25-OH Vitamin
D Total Assay uses a chemiluminescent immunoassay (CLIA) technology for the
quantitative determination of 25-(OH)D.85, 86 The HIV-1 RNA Viral Load count required
5-10 ml of blood collected in a lavender top with EDTA as the anticoagulant. The
specimen was centrifuged, separated, and frozen within 6 hours of collection. The sample
was analyzed by FDA-approved COBAS Ampliprep/COBAS TaqMan HIV-1
Test.87 In order to quantify the CD4+/CD8+ T-lymphocyte count, 5 mL blood was
collected in a lavender top tube and kept at room temperature. The specific counts were
then calculated through flow cytometry.88 The average processing time from blood draw
to laboratory result was between 3-5 days and the month of the result represented the
month of the blood draw. Month of the blood draw was used to define season of blood
collection and season was controlled for in the statistical analyses.89
23
applicable
15. AIDS diagnosis, if applicable
16. Anabolic Agent Use/Prescription
17. History of CKD
Statistical Analysis
All statistical analyses were completed with 13th Edition STATA.90 For Aim 1,
the data was analyzed for patterns of vitamin D prescriptions. Patient data based on the
frequency, dose, and form of vitamin D supplementation were recorded and grouped.
Patterns common among multiple patients were considered a vitamin D regimen.
Patients were then organized into their specific vitamin D supplementation regimens and
surveyed for an average range of 10-17 months. Patient adherence rates to vitamin D
supplementation regimens were not recorded in the electronic medical record and were
considered a limitation to this study. Using descriptive statistics, the mean, standard
deviations, and confidence intervals of the pre-treatment and subsequent vitamin D
concentrations for each type of repletion prescription were calculated. The data was
evaluated for normality.
For Aim 2, change between baseline assessment and post repletion regimen were
calculated. Baseline for this study was considered the appointment when vitamin D was
prescribed and follow-up appointments were on average 14.0 6.3 months from baseline.
In order to understand which factors affected the mean change of serum 25-(OH)D levels
between vitamin D supplementation regimens in this HIV/AIDS clinic, a linear
regression model calculated with residual sum of squares was conducted that included
change in serum 25-(OH)D from follow-up to baseline as the main outcome, with vitamin
D regimen as the main predictor adjusted by seasons of both baseline and follow-up
25
blood draws, age, sex, ethnicity (Caucasian or not Caucasian), months between blood
draws, and patient specific BMI category. The change in serum 25-(OH)D was also
compared among supplementation regimens using an adjusted ANOVA to determine if a
significant difference existed amongst regimens with p-values less than 0.05 considered
significant. Covariates were included in the model based on common practice in current
literature.
For Aim 3, a one-way ANOVA was used to determine if obese patients (BMI >30
kg/m2) at baseline had significantly different average change in serum 25-(OH)D in
ng/mL when compared to overweight (BMI: 25-29 kg/m2), normal (BMI: 19-24 kg/m2),
and underweight (BMI: <18 kg/m2) patients. Change in serum 25-(OH)D again was
calculated by subtracting follow-up 25-(OH)D serum values from baseline 25-(OH)D
serum values.
26
Results
27
Diagram 1: From the original 275 patients that met the inclusion criteria, 12 patients were
diagnosed with chronic kidney disease (all cause) and 35 patients had incomplete electronic
medical records, thus were excluded from final analysis. Final sample size included 228 HIV28
infected patients.
29
29.3 (11.4)
26.5-32.0
20.9 (9.8)
19.2-22.60
23.8 (0.2)
19.5-28.2
31.0 (12.4)
28.0-34.0
27.1 (12.5)
25.0-29.30
31.2 (11.9)
26.2-36.3
1.7 (11.8)
-1.2-4.5
6.2 (12.9)
4.0- 8.4
7.4 (15.5)
0.8-14.0
30
Figure 1: The average change in serum 25(OH)D from baseline to follow-up appointments categorized
by vitamin D regimen for all 228 patients (regimen sample sizes are designated below each regimen).
Distributions include entire ranges with 75th%-ile and 25th%-ile as the upper and lower borders of each
box, respectively. Median (50th%-ile) change is designated by the center, horizontal line.
A significant change was noted amongst all regimens with a one-way ANOVA (crude p-value = 0.04).
Pairwise comparisons, adjusted with the Tukeys method, noted significant 4.55 ng/mL increase of
patients serum 25(OH)D levels when prescribed single therapy (no change) of vitamin D2 versus single
therapy (no change) vitamin D3 (p-value = 0.048, 95% CI: 0.034-9.071). No significant differences
noted between any single therapy (D2 or D3) and the repletion and maintenance regimen (p-values = 0.92
and 0.15, respectively).
31
32
Single D2
Vitamin D Regimen
Repletion/
Maintenance
Repletion**:
50,000 (weekly)
400-5000
400-7142.9
2686.9 (
1649.4)
6521.5 (
1706.1)
3272.6 ( 2033.8)
69
135
24
Male
Female
62
7
116
19
21
3
White
Other
65
4
108
27
18
6
Mean ( SD)
48 (15)
43 (11)
47 (13)
BMI (kg/m2)*
Median (IQR)
25 (6)
24 (7)
25 (5)
43
26
67
68
12
12
38
31
70
65
11
13
46.4%
47.4%
54.2%
451 (481)
468 (421)
614 (551.5)
Maintenance:
400-5000
Sample Size
Sex
Ethnic Origin
Age (yrs.)
33
119
52
55
1
33
14
20
7
10
1
7
3
29.3 (11.4)
20.3%
20.9 (9.9)
50.4%
23.8 (10.2)
45.8%
Follow-Up: 25-(OH)D
(ng/ml)
Mean (SD)
31.0 (12.4)
27.1 (12.5)
31.2 (12.0)
15.9%
30.4%
12.5%
-4.3%
-20.0%
-33.3%
13.5 (6.7)
13.2 (6.7)
14.4 (6.2)
NRTI
NonNRTI
PI
EI
INSTI
No Treatment
*Note median (IQR) utilized for any variable not normally distributed
**50,000 IU weekly is equivalent to 7142.9 daily IU
34
54
(23.7%)
81
(35.5%)
81
(35.5%)
92
(40.4%)
93
(40.8%)
55
(24.1%)
Figure 2: The sub-sample sizes of 228 patients at both baseline and follow-up with a 25(OH)D
categorized as adequate (>30 ng/mL), inadequate (20-30 ng/mL), and deficient (<20 ng/mL) 25(OH)D
concentrations.
At baseline, 93 (40.8%) deficient, 81 (35.5%) inadequate, and 54 (23.7%) with adequate serum
25(OH)D levels were recorded. At follow-up, 55 (24.1%) deficient, 92 (40.4%) inadequate, and 81
(35.5%) adequate serum 25(OH)D levels were noted.
35
36
Adjusting for season in this specific example clarifies the effect of vitamin D
supplementation while reducing the variability in change in 25-(OH)D status associated
with UV-B exposure/endogenous production.
Vitamin D daily dosage did not seem to be a factor with change in serum 25(OH)D among all regimens. When patients were compared by average daily dose
regardless of vitamin D type, categorized: Low/Medium: 400-2000 IU and High: 50007142.9 IU, no significant differences were noted within the average change of serum 25(OH)D between baseline and follow-up appointments (adjusted p-value = 0.489).
Therefore, the specific regimen that altered both vitamin D dose and type had a more
significant effect on patients serum 25-(OH)D change than simply the dose of vitamin D.
Patients age, duration between blood draws, and season of blood draw were
significant confounders of the association between change in serum 25-(OH)D
concentrations (p-values <0.05) and vitamin D regimen. Dose strength, type, sex,
ethnicity, and BMI (continuous or categorical) were not significant confounders (Table
5). To avoid over-complicating the association model, ARV medications were not
included. Additionally, no significant interaction was observed between change in serum
25-(OH)D and ARV drug treatment, which included nucleoside and nucleotide reverse
transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors
(NNRTIs), protease inhibitors (PIs), integrase inhibitors (INSTI), or entry inhibitors
(EIs).
37
95% CI
p-value
7.02 (4.18)
Reference
5.90 (2.95)
-1.22, 15.27
0.095
0.09, 11.72
0.047*
-1.44 (2.08)
Reference
-5.55, 2.66
0.489
-2.29 (4.15)
Reference
-10.46, 5.89
0.582
Age
Sex
Male
Female
Ethnicity
Caucasian
Not Caucasian
0.153 (0.068)
0.019, 0.287
0.026*
-3.13 (2.48)
Reference
-8.03, 1.76
0.209
-1.46 (2.31)
Reference
-6.01, 3.10
0.529
-0.678 (0.13)
-0.93, -0.42
<0.0001*
5.71 (2.31)
Reference
5.66 (2.38)
3.77 (2.4)
1.16, 10.26
0.014*
0.97, 10.36
-0.98, 8.53
0.018*
0.120
BMI, continuous
-0.01 (0.36)
-0.70, 0.72
0.975
-8.30, 2.03
-14.93, 4.41
-12.36,
23.51
0.231
0.285
Dose Strength
High (5000-7142.9 IU)
Low/Med (400-2000 IU)
Dose Type
Vitamin D2 (ergo-)
Vitamin D3 (chole-)
Underweight/Normal
Overweight
Obese
0 (constant)
Reference
-3.18 (2.64)
-5.26 (4.91)
5.58 ( 9.10)
0.541
39
compared to non-obese (BMI: 30 kg/m2) patients when analyzing change in serum 25(OH)D.
40
Figure 3: The average change in serum 25(OH)D from baseline to follow-up appointments categorized by
baseline BMI (kg/m2). Categories were defined as underweight (16-18 kg/m2), normal (19-24 kg/m2),
overweight (25-29 kg/m2), and obese (30-45 kg/m2). Respective sample sizes are listed below each.
One-way ANVOA lacked significance amongst BMI categories (p-value = 0.121). Pairwise comparisons
adjusted by Tukeys method also did not find any statistical (p-values >0.05).
41
Figure 3: The average change in serum 25(OH)D from baseline to follow-up appointments categorized
by baseline BMI (kg/m2). Categories were defined as underweight/normal (16-24 kg/m2), overweight
(25-29 kg/m2), and obese (30-45 kg/m2). Respective sample sizes are listed below each.
One-way ANVOA did not note significant group difference (p-value = 0.10). Pairwise comparisons
adjusted by Tukeys method also did not find any statistical (p-values >0.05).
42
Discussion
concentrations, this was not observed in our cohort. This could potentially be due to lack
of patient adhearance to vitamin D supplementation regimen, thus altering overall change
in serum 25-(OH)D among these factors. Patient adherence to prescribed vitamin D
regimens was not included in patients electronic medical records. In addition, small
sample size and limited variability in dose strength, ethnicity, and ARV regimen may
explain the observed lack of association of these factors with change in vitamin D.
44
45
either D2 or D3) was a higher daily dose than the single vitamin D3 regimen and lower
than the single therapy D2 therapy (repletion/maintenance: 3272.6 ( 2033.8) IU daily,
single D3: 2686.9 ( 1649.4) IU daily, single vitamin D2: 6521.5 ( 1706.1) IU daily).
Importantly, patients in the repletion/maintainence regimen did not have a higher daily
dose of vitamin D than the other regimens. Also, the single therapy vitamin D2 regimen,
which had an average daily dose of 6521.5 ( 1706.1) IU did not significantly increase
serum 25-(OH)D concentrations greater than all other regimens. Therefore, the vitamin D
regimen that included both alterations in vitamin D dose and changed from vitamin D2 to
vitamin D3 was more effective at changing serum 25-(OH)D concentration in HIVinfected patients.
46
Study Limitations
Despite efforts to control for seasonality by limiting serum 25-(OH)D
concentrations to similar seasons at both baseline and follow-up appointments, the
majority of patients had follow-up appointments with varying seasons from baseline.
Thus, seasons of blood draw were limited to summer months (March to August) or to the
winter months (September to February). Condensing twelve months to two seasons
limited this studys generalizability as to which specific month altered 25(OH) D serum
concentrations the greatest.
Also, the lack of differentiation between 25-(OH)D2 and 25-(OH)D3 due to
OHSUs serum 25-(OH)D assay limited interpretability of which vitamin D type is most
effective at increasing vitamin D nutriture, especially since vitamin D2 supplementation
in both the single D type and repletion/maintenance regimen increased serum 25-(OH)D
47
48
regimens.
There were no adverse reports noted in the electronic medical records from the
vitamin D supplementation and no evidence of toxicity among any vitamin D regimens.
Future investigations should consider supplementing only high-dose vitamin D within an
HIV-Infected population in order to increase serum 25-(OH)D concentrations
significantly.
Conclusion
Vitamin D deficiency is prevalent in HIV-infected patients, including among
HIV-infected patients treated at OHSU. Supplementation, therefore, is vital to increasing
25-(OH)D stores within this complex population. Vitamin D status is generally decreased
by lack of sunlight (UV-B exposure), obesity, and ethnicity.4, 27 HIV-infected patients
metabolism of vitamin D is further challenged by ARV medications, HIV-related
inflammation, and potential fat-malabsorptive issues.27 A repletion/maintenance regimen
of high-dose vitamin D2 at 50,000 IU weekly and then a lower daily dose of either
vitamin D2 or D3 increased serum 25-(OH)D concentrations more than any other single D
type regimen. Future studies should continue to adjust for known confounders when
analyzing change in vitamin D status but also adjust for signs/symptoms of fatmalabsorption (i.e. steatorrhea) and indicators of patient adherence. Although this study
provides guidance on optimal vitamin D supplementation regimens for HIV-infected
patients, further research is needed, including studies specifically investigating HIVspecific vitamin D deficiency.
49
References
1.
2.
Mueller NJ, Fux CA, Ledergerber B, et al. High prevalence of severe vitamin D
deficiency in combined antiretroviral therapy-naive and successfully treated Swiss
HIV patients. Aids 2010;24(8):1127-34. doi: 10.1097/QAD.0b013e328337b161.
3.
4.
Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and
prevention of vitamin D deficiency: an Endocrine Society clinical practice
guideline. J Clin Endocrinol Metab 2011;96(7):1911-30. doi: 10.1210/jc.20110385.
5.
Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of
cardiovascular disease. Circulation 2008;117(4):503-11. doi:
10.1161/CIRCULATIONAHA.107.706127.
6.
Munger KL, Zhang SM, O'Reilly E, et al. Vitamin D intake and incidence of
multiple sclerosis. Neurology 2004;62(1):60-5.
7.
50
8.
9.
Ngo DT, Sverdlov AL, McNeil JJ, Horowitz JD. Does vitamin D modulate
asymmetric dimethylarginine and C-reactive protein concentrations? Am J Med
2010;123(4):335-41. doi: 10.1016/j.amjmed.2009.09.024.
10.
11.
12.
Liu PT, Stenger S, Tang DH, Modlin RL. Cutting edge: vitamin D-mediated
human antimicrobial activity against Mycobacterium tuberculosis is dependent on
the induction of cathelicidin. The Journal of Immunology 2007;179(4):2060.
13.
Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcomaassociated herpesvirus-like DNA sequences in AIDS-related body-cavity-based
lymphomas. NEnglJMed 1995;332(18):1186-91. doi:
10.1056/NEJM199505043321802.
51
14.
15.
Lake JE, Adams JS. Vitamin D in HIV-Infected Patients. Curr HIV/AIDS Rep
2011;8(3):133-41. doi: 10.1007/s11904-011-0082-8.
16.
17.
Viard JP, Souberbielle JC, Kirk O, et al. Vitamin D and clinical disease
progression in HIV infection: results from the EuroSIDA study. Aids
2011;25(10):1305-15. doi: 10.1097/QAD.0b013e328347f6f7.
18.
19.
Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous
synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will
not promote vitamin D3 synthesis in human skin. Journal of Clinical
Endocrinology & Metabolism 1988;67(2):373.
20.
52
21.
Ginde AA, Liu MC, Camargo CA, Jr. Demographic differences and trends of
vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med
2009;169(6):626-32. doi: 10.1001/archinternmed.2008.604.
22.
Gallagher JC, Riggs BL, Eisman J, Hamstra A, Arnaud SB, DeLuca HF. Intestinal
calcium absorption and serum vitamin D metabolites in normal subjects and
osteoporotic patients: effect of age and dietary calcium. J Clin Invest
1979;64(3):729-36. doi: 10.1172/JCI109516.
23.
24.
25.
26.
27.
Dao CN, Patel P, Overton ET, et al. Low vitamin D among HIV-infected adults:
prevalence of and risk factors for low vitamin D Levels in a cohort of HIVinfected adults and comparison to prevalence among adults in the US general
population. Clinical Infectious Diseases 2011;52(3):396.
53
28.
Gordon CM, DePeter KC, Feldman HA, Grace E, Emans SJ. Prevalence of
vitamin D deficiency among healthy adolescents. Archives of pediatrics &
adolescent medicine 2004;158(6):531-7.
29.
Bodnar LM, Simhan HN, Powers RW, Frank MP, Cooperstein E, Roberts JM.
High prevalence of vitamin D insufficiency in black and white pregnant women
residing in the northern United States and their neonates. JNutr 2007;137(2):44752.
30.
Yetley EA, Pfeiffer CM, Schleicher RL, et al. NHANES monitoring of serum 25hydroxyvitamin D: a roundtable summary. JNutr 2010;140(11):2030S-45S.
31.
32.
33.
34.
Dannhauser A, van Staden AM, van der Ryst E, et al. Nutritional status of HIV-1
seropositive patients in the Free State Province of South Africa: anthropometric
and dietary profile. Eur J Clin Nutr 1999;53(3):165-73.
54
35.
36.
37.
38.
Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIVinfected adults. NEnglJMed 2005;352(1):48-62. doi: 10.1056/NEJMra041811.
39.
40.
41.
55
42.
43.
44.
45.
DeLuca HF, Holick MF, Schnoes HK, Suda T, Cousins RJ. Isolation and
identification of 1, 25-dihydroxycholecalciferol. A metabolite of vitamin D active
in intestine. Biochemistry (NY) 1971;10(14):2799.
46.
Holick MF, Frommer JE, McNeill SC, Richtand NM, Henley JW, Potts JT, Jr.
Photometabolism of 7-dehydrocholesterol to previtamin D3 in skin. Biochem
Biophys Res Commun 1977;76(1):107-14.
47.
48.
Hull SE, Leban I, Main P, White PS, Woolfson MM. The crystal and molecular
structure of ergocalciferol (vitamin D2). Acta Crystallographica Section B:
Structural Crystallography and Crystal Chemistry 1976;32(8):2374.
56
49.
Omdahl JL, Morris HA, May BK. Hydroxylase enzymes of the vitamin D
pathway: expression, function, and regulation. Annu Rev Nutr 2002;22(1):139-66.
doi: 10.1146/annurev.nutr.22.120501.150216.
50.
51.
52.
Hunt RD, Garcia FG, Walsh RJ. A comparison of the toxicity of ergocalciferol
and cholecalciferol in rhesus monkeys (Macaca mulatta). J Nutr 1972;102(8):97586.
53.
54.
Davis CD. Vitamin D and cancer: current dilemmas and future research needs.
Am J Clin Nutr 2008;88(2):565S-9S.
55.
Brannon PM, Yetley EA, Bailey RL, Picciano MF. Overview of the conference
"Vitamin D and Health in the 21st Century: an Update". Am J Clin Nutr
2008;88(2):483S-90S.
57
56.
Takeyama K, Kitanaka S, Sato T, Kobori M, Yanagisawa J, Kato S. 25Hydroxyvitamin D3 1alpha-hydroxylase and vitamin D synthesis. Science
1997;277(5333):1827-30.
57.
Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference
intakes for calcium and vitamin D from the Institute of Medicine: what clinicians
need to know. Journal of Clinical Endocrinology & Metabolism 2011;96(1):53.
58.
Hoenderop JG, MLLER D, VAN DER KEMP AW, et al. Calcitriol controls the
epithelial calcium channel in kidney. Journal of the American Society of
Nephrology 2001;12(7):1342-9.
59.
60.
61.
62.
63.
Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4 lymphocytes
as prognostic markers of HIV-1 infection. AnnInternMed 1997;126(12):946.
58
64.
65.
66.
Crowe SM, Carlin JB, Stewart KI, Lucas CR, Hoy JF. Predictive value of CD4
lymphocyte numbers for the development of opportunistic infections and
malignancies in HIV-infected persons. J Acquir Immune Defic Syndr
1991;4(8):770-6.
67.
68.
Centers for Disease C, Prevention. HIV in the United States: at a glance. Atlanta:
CDC 2012.
69.
59
70.
71.
Rapuri PB, Gallagher JC, Haynatzka V. Protein intake: effects on bone mineral
density and the rate of bone loss in elderly women. Am J Clin Nutr
2003;77(6):1517-25.
72.
Schafer JJ, Manlangit K, Squires KE. Bone health and human immunodeficiency
virus infection. Pharmacotherapy 2013;33(6):665-82. doi: 10.1002/phar.1257.
73.
74.
75.
76.
77.
Bhalla AK, Amento EP, Clemens TL, Holick MF, Krane SM. Specific highaffinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood
mononuclear cells: presence in monocytes and induction in T lymphocytes
following activation. J Clin Endocrinol Metab 1983;57(6):1308-10. doi:
10.1210/jcem-57-6-1308.
60
78.
Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin Dmediated human antimicrobial response. Science 2006;311(5768):1770-3. doi:
10.1126/science.1123933.
79.
80.
Cantorna MT, Zhu Y, Froicu M, Wittke A. Vitamin D status, 1,25dihydroxyvitamin D3, and the immune system. Am J Clin Nutr 2004;80(6
Suppl):1717S-20S.
81.
Ahmed B, Jaspan JB. Case report: hypercalcemia in a patient with AIDS and
Pneumocystis carinii pneumonia. Am J Med Sci 1993;306(5):313-6.
82.
83.
Foissac F, Trluyer JM, Souberbielle JC, Rostane H, Urien S, Viard JP. Vitamin
D3 supplementation scheme in HIVinfected patients based upon
pharmacokinetic modelling of 25hydroxycholecalciferol. BrJClinPharmacol
2013;75(5):1312.
84.
85.
61
86.
Geier J. Oregon Health & Science University Central Lab Vitamin D Assay.
2014.
87.
88.
89.
90.
StataCorp. 2013. Stata Statistical Software: Release 13. College Station TSL.
62
Design
CrossSectional
(Data from 5
cohorts)
Participants/
Specimens
2994 eligible
participants
(Average 45
y/o & male)
Retrospective
assessment of
vit D by
season and
initiation of
cART
Outcomes
Vitamin D deficiency/
insufficiency in 86.7% (31.1%
w/ deficiency)
Duration
Screening
every 3-6
months
Selection Criteria
Exclusion: No
Vitamin D screen, 3
months ARV Tx, Hx
of osteoporosis &
severe renal
impairment
211 HIV
Infected
patients'
stored plasma
samples,
mainly male
Plasma
collected
every 6
months
Crosssectional
(limited to the
winter/spring)
57
Ambulatory,
77% male
and average
46 y/o
4 months
(collected
plasma
throughout)
Exclusion: Not
seeking HIV medical
care at MGH HIV
Clinic (Boston, MA)
Longitudinal
No prev. CV
disease,
Mean: 59 y/o,
55% female,
all white
7.6 years of
follow-up
(Mean 5.4
yrs.)
Exclusion: Mainly,
no previous Hx of
chronic disease (esp.
CV)
63
5. Vitamin D intake
and incidence of
multiple sclerosis
Prospective
cohort
Female, I:
121,700 aged
30 -55 years;
II: 116,671
aged 25- 42
years
6. Intake of vitamin
D and risk of type 1
diabetes: a birthcohort study
Birth-cohort
10,334
Dietary vitamin D
infants (51% supplementation is associated
boy/49% girl) with reduced risk of type 1
diabetes
7. Vitamin D
concentration of
HIV-infected women
and its association
with HIV disease
progression,
anemia, and
mortality.
9. Meinken C. Tolllike receptor
triggering of a
vitamin D-mediated
human antimicrobial
response
10. The
antimicrobial
peptide LL-37
inhibits HIV-1
Clinical Trial
(large)
HIV Infected
Females of
Tanzania
(inc.
pregnant)
In-Vitro
Monocyte/M
acrophages
(TLR2/1)
In-Vitro
Antimicrobia
l peptide LL37
Supplementation of the
African American serum with
25-(OH)D3 to a physiologic
range restored TLR repletion
of cathelicidin mRNA
(+antimicrobial)
HIV-1 inhibitory effect
independent of FPRL-1
signaling
64
replication
11. Vitamin D in
HIV-infected
patients
Observational
HIV Infected
patients (<18
yrs. old)
12. Dietary
Reference Intakes
for Calcium and
Vitamin D
13. Influence of
season and latitude
on the cutaneous
synthesis of vitamin
D3: exposure to
winter sunlight in
Boston and
Edmonton will not
promote vitamin D3
synthesis in human
skin
Systematic
evidencebased reviews
American &
Canadian
citizens
Crosssectional
Boston &
Edmonton
residents
65
varies
varies
American &
Canadian citizens
(w/ involvement in
Vit. D study)
Must reside in
specific cities
Seasonal
14. Chronic
sunscreen use
decreases
circulating
concentrations of
25-(OH)D: a
preliminary study
PlaceboControlled
15. Demographic
Differences and
Trends of Vitamin D
Insufficiency in the
US Population,
1988-2004
Observational
(survey)
16. Intestinal
Placebocalcium absorption
Controlled
and serum vitamin D
metabolites in
normal subjects and
osteoporotic
patients: effect of
age and dietary
calcium
20 long-term
users of paminobenzoi
c acid
(PABA) and
20 in controls
matched by
age and
exposure to
sunlight
18,883
participants
in NHANES
III and
13,369
participants
in NHANES
2001-2004
94 normal
subjects (77
women and
17 men) 3090 y/o
One-time lab
visit
~9 years
3 months
Ambulatory, good
health, not on
supplements, w/o hip
fractures or back
pain
66
17. Decreased
bioavailability of
vitamin D in obesity
PlaceboControlled
Healthy,
white, obese
[body mass
index (BMI;
in kg/m2)
30] and
matched lean
control
subjects
(BMI 25)
661 HIVinfected
patients
Retrospective
19. Different
strategies of 25OH
vitamin D
supplementation in
HIV+ subjects
Prospective
Cohort
191 HIVinfected
patients
Review
Multiple
studies
(Notable:
SUN, HOPS,
ASSERT,
PREPARE,
iPrEx, and
EuroSIDA)
48 hours (24
hr. to screen)
Exclusion: Hx of
hepatic/renal
disorders and taking
vitamin D
supplements,
anticonvulsant
medications, or
corticosteroids
1 yr. (June
2004-2005)
March-May
2011
Variable time
frame of
study
(Review pub.
2013)
25OH vitamin D
levels <30 ng/mL,
Caucasian ethnicity,
HIV infection, and
current cART
treatment w/o
changes for >12 mo.
HIV Infected
Patients
67